RadioGel™ is an yttrium-90 (90Y) based injectable Precision Radionuclide Therapy (PRnT) device
for the treatment of cancerous tumors in animals (IsoPet®) and humans (RadioGel™).
Precision Radionuclide Therapy (PRnT) uses highly localized radiation to destroy,
cancerous tumors by placing a safe beta emitting radioactive isotope directly inside the treatment
area using the company’s proprietary hydrogel technology.
Radiogel™ is a hydrogel liquid containing tiny Yttrium-90 (90Y) phosphate microparticles that may be administered directly into a tumor.
The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range
beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
The Isopet® Solutions division utilized university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at
the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
IsoPet® Therapy is readily available at The University of Missouri and select Regional Clinics.
Learn More
( Mike Korenko, Sc. D. • CEO • President | August 7, 2023 Press Release )
Richland WA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that it certified three additional clinics to offer Isopet® Precision Radionuclide Therapy (PRnT).
The three new clinics are The Myhre Equine Clinic, located in Rochester, New Hampshire, the Hopkinton Animal Hospital, located in Weare, New Hampshire and the Indian Creek Veterinary Hospital, located in Fort Wayne, Indiana.